Skip to content

Breakthrough: Catalyzing R&D to End TB

  • Chad Cipiti

There is great hope for ending tuberculosis (TB)—the world’s leading infectious disease—thanks to both scientific progress and increased ambition from policymakers.

Read more

2016 Report on TB Research Funding Trends

  • Chad Cipiti

Tuberculosis (TB) killed 1.8 million people in 2015, making it the most deadly infectious disease worldwide, but funding for research into better TB prevention, diagnosis, and treatment dropped by US$53.4 million, according to Treatment Action Group’s 2016 Report on Tuberculosis Research Funding Trends, 2005–2015: No Time to Lose.

Read more

TAGline Fall 2016

  • Chad Cipiti

Health, Human Rights, and Social Justice: maximizing HIV, tuberculosis (TB), and viral hepatitis outcomes depends on the availability of state-of-the-art diagnostic and prognostic tools, engagement in expert and supportive care, and access to safe and effective drugs.

Read more

Petition to BRICS countries to triple funding for TB R&D

  • Chad Cipiti

Tuberculosis (TB) is the world’s deadliest infectious disease, and research into new ways to prevent, diagnose, and treat TB is urgently needed. BRICS countries—Brazil, Russia, India, China, and South Africa—are home to nearly half of all the world’s new TB cases and deaths, yet only provide 4 percent of funding for R&D to prevent them. In anticipation of the 6th Meeting of the BRICS Health Ministers, please join our call for BRICS countries to triple funding for TB research and development (R&D).

Read more

Countering the Contagion of Racism Through Resistance

  • Chad Cipiti

Upholding narratives of Black science and treatment activism, and community mobilization in HIV/AIDS and TB By Suraj Madoori In February 2016, startling data released by the Centers for Disease Control and Prevention (CDC) at the Conference of Retroviruses and Opportunistic…

Read more

Science and Solidarity

  • Chad Cipiti

Using human rights to strengthen TB research and access By Mike Frick Editor’s note: The following is based on the transcript of a plenary address delivered by the author at TB2016, a two-day TB conference held before the July International…

Read more

TAG Welcomes Delamanid’s Inclusion in the Stop TB Partnership’s Global Drug Facility

  • Chad Cipiti

Treatment Action Group (TAG) congratulates the Stop TB Partnership and Otsuka Pharmaceutical for arranging for the inclusion of delamanid, an important new medicine for treating some cases of multidrug-resistant tuberculosis (MDR-TB), in the Global Drug Facility (GDF). TB is the leading infectious cause of death globally, and new medicines to treat drug-resistant strains of TB are urgently needed.

Read more
Back To Top